These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 38750555)

  • 21. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
    Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA
    Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Additional germline findings from a tumor profiling program.
    Stjepanovic N; Stockley TL; Bedard PL; McCuaig JM; Aronson M; Holter S; Semotiuk K; Leighl NB; Jang R; Krzyzanowska MK; Oza AM; Gupta A; Elser C; Ahmed L; Wang L; Kamel-Reid S; Siu LL; Kim RH
    BMC Med Genomics; 2018 Aug; 11(1):65. PubMed ID: 30092803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion
    Vidula N; Rich TA; Sartor O; Yen J; Hardin A; Nance T; Lilly MB; Nezami MA; Patel SP; Carneiro BA; Fan AC; Brufsky AM; Parker BA; Bridges BB; Agarwal N; Maughan BL; Raymond VM; Fairclough SR; Lanman RB; Bardia A; Cristofanilli M
    Clin Cancer Res; 2020 Jun; 26(11):2546-2555. PubMed ID: 32034076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted mutation detection in breast cancer using MammaSeqâ„¢.
    Smith NG; Gyanchandani R; Shah OS; Gurda GT; Lucas PC; Hartmaier RJ; Brufsky AM; Puhalla S; Bahreini A; Kota K; Wald AI; Nikiforov YE; Nikiforova MN; Oesterreich S; Lee AV
    Breast Cancer Res; 2019 Feb; 21(1):22. PubMed ID: 30736836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study.
    Cheng HF; Tsai YF; Liu CY; Hsu CY; Lien PJ; Lin YS; Chao TC; Lai JI; Feng CJ; Chen YJ; Chen BF; Chiu JH; Tseng LM; Huang CC
    Breast Cancer Res; 2023 Dec; 25(1):152. PubMed ID: 38098088
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA.
    Schrader KA; Cheng DT; Joseph V; Prasad M; Walsh M; Zehir A; Ni A; Thomas T; Benayed R; Ashraf A; Lincoln A; Arcila M; Stadler Z; Solit D; Hyman DM; Zhang L; Klimstra D; Ladanyi M; Offit K; Berger M; Robson M
    JAMA Oncol; 2016 Jan; 2(1):104-11. PubMed ID: 26556299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paired tumor sequencing and germline testing in breast cancer management: An experience of a single academic center.
    Elliott E; Speare V; Coggan J; Espenschied C; LaDuca H; Yussuf AF; Burgess K; Gray P; Cobleigh M; Rao R; Patel J; Kuzel T; Buckingham LE; Usha L
    Cancer Rep (Hoboken); 2020 Dec; 3(6):e1287. PubMed ID: 32881420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients.
    Tsui DWY; Cheng ML; Shady M; Yang JL; Stephens D; Won H; Srinivasan P; Huberman K; Meng F; Jing X; Patel J; Hasan M; Johnson I; Gedvilaite E; Houck-Loomis B; Socci ND; Selcuklu SD; Seshan VE; Zhang H; Chakravarty D; Zehir A; Benayed R; Arcila M; Ladanyi M; Funt SA; Feldman DR; Li BT; Razavi P; Rosenberg J; Bajorin D; Iyer G; Abida W; Scher HI; Rathkopf D; Viale A; Berger MF; Solit DB
    Genome Med; 2021 May; 13(1):96. PubMed ID: 34059130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor genome analysis includes germline genome: are we ready for surprises?
    Catenacci DV; Amico AL; Nielsen SM; Geynisman DM; Rambo B; Carey GB; Gulden C; Fackenthal J; Marsh RD; Kindler HL; Olopade OI
    Int J Cancer; 2015 Apr; 136(7):1559-67. PubMed ID: 25123297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The detection of germline and somatic BRCA1/2 genetic variants through parallel testing of patients with high-grade serous ovarian cancer: a national retrospective audit.
    Frugtniet B; Morgan S; Murray A; Palmer-Smith S; White R; Jones R; Hanna L; Fuller C; Hudson E; Mullard A; Quinton AE
    BJOG; 2022 Feb; 129(3):433-442. PubMed ID: 34657373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidental germline findings during molecular profiling of tumor tissues for precision oncology: molecular survey and methodological obstacles.
    Lebedeva A; Shaykhutdinova Y; Seriak D; Ignatova E; Rozhavskaya E; Vardhan D; Manicka S; Sharova M; Grigoreva T; Baranova A; Mileyko V; Ivanov M
    J Transl Med; 2022 Jan; 20(1):29. PubMed ID: 35033101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic applications of germline testing for cancer predisposition genes in Asia in the real world.
    Cheo SW; Ong PY; Ow SGW; Chan GHJ; Tan DSP; Lim YW; Kong HL; Wong ALA; Lim SE; Walsh RJ; Wong ASC; Low JJH; Ngoi NYL; Lim JSL; Lee SC
    ESMO Open; 2024 Jun; 9(6):103482. PubMed ID: 38833967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene Panel Tumor Testing in Ovarian Cancer Patients Significantly Increases the Yield of Clinically Actionable Germline Variants beyond
    Barbosa A; Pinto P; Peixoto A; Guerra J; Pinto C; Santos C; Pinheiro M; Escudeiro C; Bartosch C; Silva J; Teixeira MR
    Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 33008098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The emerging clinical relevance of genomic profiling in neuroendocrine tumours.
    Burak GI; Ozge S; Cem M; Gulgun B; Zeynep DY; Atil B
    BMC Cancer; 2021 Mar; 21(1):234. PubMed ID: 33676450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Feasibility and Clinical Utility of Reporting Hereditary Cancer Predisposition Pathogenic Variants Identified in Research Germline Sequencing: A Prospective Interventional Study.
    Hutchcraft ML; Zhang S; Lin N; Pickarski JC; Belcher EA; Wei S; Bocklage T; Miller RW; Villano JL; Cavnar MJ; Kim J; Arnold SM; Ueland FR; Kolesar JM
    JCO Precis Oncol; 2024 Jan; 8():e2300266. PubMed ID: 38295319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study.
    Smyth LM; Reichel JB; Tang J; Patel JAA; Meng F; Selcuklu DS; Houck-Loomis B; You D; Samoila A; Schiavon G; Li BT; Razavi P; Piscuoglio S; Reis-Filho JS; Taylor BS; Baselga J; Solit DB; Hyman DM; Berger MF; Chandarlapaty S
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequency of Pathogenic Germline Mutations in Early and Late Onset Familial Breast Cancer Patients Using Multi-Gene Panel Sequencing: An Egyptian Study.
    Nassar A; Zekri AN; Kamel MM; Elberry MH; Lotfy MM; Seadawy MG; Hassan ZK; Soliman HK; Lymona AM; Youssef ASE
    Genes (Basel); 2022 Dec; 14(1):. PubMed ID: 36672847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic head and neck squamous cell carcinoma.
    Galot R; van Marcke C; Helaers R; Mendola A; Goebbels RM; Caignet X; Ambroise J; Wittouck K; Vikkula M; Limaye N; Machiels JH
    Oral Oncol; 2020 May; 104():104631. PubMed ID: 32169746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
    Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
    Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.